Technology adds Potential for Speeding Discovery to Manufacture

Novasep (France), a leading supplier of services and technologies for the life sciences industry and the UK’s Centre for Process Innovation (CPI), have equipped the UK National Biologics Manufacturing Centre with BioSC Lab technology for protein purification.

With a mandate to get UK companies up and running in technological areas that offer the largest potential impact on the future of UK and global manufacturing, the CPI provides services to SMEs that decrease time to market for novel products or processes.

 “The National Biologics Manufacturing Centre has been designed to help companies of all sizes to develop, prove and commercialise new and improved processes and technologies for biopharmaceutical manufacture,” said Dr Chris Dowle, director of biologics at CPI. “The installation of Novasep’s BioSC Lab will be a valuable asset to customers using the centre."

BiosSC Lab can purify a few grams of proteins per day, enabling users to develop cost effective, high yield production processes while maintaining the same quality attributes of the protein.

“Novasep and CPI both use innovation as a strategy to solve problems in biopharmaceutical manufacturing,” said Alain Lamproye, president of the Biopharma Business unit at Novasep. “We believe our BioSC Lab will contribute to helping the UK biopharma sector step into the future of manufacturing, where the demand is for simplification and flexibility.”